{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:52:11Z","timestamp":1794027131872,"version":"4.8.0"},"reference-count":325,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04389-x","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:09:12Z","timestamp":1781806152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Next-generation CAR-NK cell therapy: engineering strategies, translational challenges, and future perspectives in cancer immunotherapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Minoo","family":"Bakhtiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Nickho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh Lavi","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Hoseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Baharlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"4389_CR1","doi-asserted-by":"crossref","unstructured":"Li Yuxi YY, Huang Y-F, Cui R, Sun J, Lyu R, Wang T, Xiong W, Wang YYQ, Liu W, An G, Sui W, Xu Y. Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi. Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression. 28 Nov 2023.","DOI":"10.1182\/blood-2023-186068"},{"key":"4389_CR2","doi-asserted-by":"crossref","unstructured":"Chen YYF, Jiang L, Li J, Zhu X, Bao Y. programmed cell death protein 1 (PD-1),. Gene-Modified NK-92MI Cells Expressing a Chimeric CD16-BB-Zeta or CD64-BB-Zeta Receptor Exhibit Enhanced Cancer-Killing Ability in Combination With Therapeutic Antibody. Oncotarget. 2017.","DOI":"10.18632\/oncotarget.16201"},{"key":"4389_CR3","unstructured":"Shicheng Sun KJW, Liani O, Strumila K, Ella SM, Ng AG, Elefanty, Edouard G. Mar. Stanley Lymphoid cell development from fetal hematopoietic progenitors and human pluripotent stem cells. Immunol Rev 20 2023."},{"key":"4389_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3389\/fimmu.2019.02078","volume":"10","author":"F Cichocki","year":"2019","unstructured":"Cichocki F, Grzywacz B, Miller JS. Human NK Cell Development: One Road or Many? Front Immunol. 2019;10:2078.","journal-title":"Front Immunol"},{"key":"4389_CR5","doi-asserted-by":"crossref","unstructured":"Ke Ma ZZ, Yu M. Apr. Natural Killer Cells, as the Rising Point in Tissues, Are Forgotten in the Kidney. Biomolecules 26 2023.","DOI":"10.3390\/biom13050748"},{"key":"4389_CR6","doi-asserted-by":"crossref","unstructured":"Aur\u00e9lie S, Clottu MH, Fluder N, Karampetsou MP. Denis Comte Innate Lymphoid Cells in Autoimmune Diseases. Frontiers in Immunology. 7 Jan 2022.","DOI":"10.3389\/fimmu.2021.789788"},{"issue":"1","key":"4389_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022;10(1):12.","journal-title":"Biomark Res"},{"key":"4389_CR8","doi-asserted-by":"crossref","unstructured":"Leupold T. Nov SW. ILCs\u2014Crucial Players in Enteric Infectious Diseases. Int J Mol Sci 1 2022.","DOI":"10.3390\/ijms232214200"},{"issue":"4","key":"4389_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","volume":"180","author":"P Dogra","year":"2020","unstructured":"Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, et al. Tissue determinants of human NK cell development, function, and residence. Cell. 2020;180(4):749-63. e13.","journal-title":"Cell"},{"key":"4389_CR10","doi-asserted-by":"crossref","unstructured":"Bryceson YTMM, Barber DF, Ljunggren HG, Long EO. Cytolytic Granule Polarization and Degranulation Controlled by Different Receptors in Resting NK Cells. 2005.","DOI":"10.1084\/jem.20051143"},{"key":"4389_CR11","doi-asserted-by":"crossref","unstructured":"Gunesch JTAL, Mahapatra S, Deering RP, Kowalko JE. Sleiman P, al e. Genome-Wide Analyses and Functional Profiling of Human NK Cell Lines. Mol Immunol. 2019.","DOI":"10.1016\/j.molimm.2018.07.015"},{"key":"4389_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fimmu.2016.00585","volume":"7","author":"R Rajalingam","year":"2016","unstructured":"Rajalingam R. The impact of HLA class I-specific killer cell immunoglobulin-like receptors on antibody-dependent natural killer cell-mediated cytotoxicity and organ allograft rejection. Front Immunol. 2016;7:585.","journal-title":"Front Immunol"},{"issue":"1","key":"4389_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/imr.12319","volume":"267","author":"PM Saunders","year":"2015","unstructured":"Saunders PM, Vivian JP, O\u2019Connor GM, Sullivan LC, Pymm P, Rossjohn J, et al. A bird\u2019s eye view of NK cell receptor interactions with their MHC class I ligands. Immunol Rev. 2015;267(1):148\u201366.","journal-title":"Immunol Rev"},{"key":"4389_CR14","doi-asserted-by":"crossref","unstructured":"John M, Cronk EF, Brown MG. Licensing Natural Killers for Antiviral Immunity. Pathogens. 2021.","DOI":"10.3390\/pathogens10070908"},{"issue":"1","key":"4389_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/imr.12600","volume":"280","author":"DH Raulet","year":"2017","unstructured":"Raulet DH, Marcus A, Coscoy L. Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells. Immunol Rev. 2017;280(1):93\u2013101.","journal-title":"Immunol Rev"},{"key":"4389_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225\u201374.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"4389_CR17","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"T Anagnostou","year":"2020","unstructured":"Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. The Lancet Haematology. 2020;7(11):e816\u201326.","journal-title":"The Lancet Haematology"},{"issue":"8","key":"4389_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"4389_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847008","volume":"13","author":"M Soldierer","year":"2022","unstructured":"Soldierer M, Bister A, Haist C, Thivakaran A, Cengiz SC, Sendker S, et al. Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies. Front Immunol. 2022;13:847008.","journal-title":"Front Immunol"},{"key":"4389_CR20","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2019-131373","volume":"134","author":"R Bjordahl","year":"2019","unstructured":"Bjordahl R, Gaidarova S, Goodridge JP, Mahmood S, Bonello G, Robinson M, et al. FT576: a novel multiplexed engineered off-the-shelf natural killer cell immunotherapy for the dual-targeting of CD38 and Bcma for the treatment of multiple myeloma. Blood. 2019;134:3214.","journal-title":"Blood"},{"issue":"1","key":"4389_CR21","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","volume":"13","author":"F Cichocki","year":"2022","unstructured":"Cichocki F, Bjordahl R, Goodridge JP, Mahmood S, Gaidarova S, Abujarour R, et al. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nat Commun. 2022;13(1):7341.","journal-title":"Nat Commun"},{"issue":"6","key":"4389_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. New England Journal of Medicine. 2020;382(6):545\u201353.","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"4389_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-017-2055-2","volume":"67","author":"P Nowakowska","year":"2018","unstructured":"Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunology, Immunotherapy. 2018;67(1):25\u201338.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"12","key":"4389_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41417-020-0174-y","volume":"27","author":"K Choucair","year":"2020","unstructured":"Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020;27(12):841\u201353.","journal-title":"Cancer Gene Ther"},{"key":"4389_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.01.007","author":"LMA Ruggeri","year":"2005","unstructured":"Ruggeri LMA, Capanni M, Martelli MF, Velardi A. Exploitation of Alloreactive NK Cells in Adoptive Immunotherapy of Cancer. Curr Opin Immunol. 2005. https:\/\/doi.org\/10.1016\/j.coi.2005.01.007.","journal-title":"Curr Opin Immunol"},{"key":"4389_CR26","doi-asserted-by":"crossref","unstructured":"Sheng L, Mu Q, Wu X, Yang S, Zhu H, Wang J et al. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation. Front Immunol. 2020;Volume 11\u20132020.","DOI":"10.3389\/fimmu.2020.01534"},{"issue":"1","key":"4389_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"S-Y Wu","year":"2020","unstructured":"Wu S-Y, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"key":"4389_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403524","author":"JRTA Passweg","year":"2004","unstructured":"Passweg JRTA, Meyer-Monard S, Heim D, Stern M, Kuhne T, et al. Purified Donor NK-Lymphocyte Infusion to Consolidate Engraftment After Haploidentical Stem Cell Transplantation. Leukemia. 2004. https:\/\/doi.org\/10.1038\/sj.leu.2403524.","journal-title":"Leukemia"},{"issue":"4","key":"4389_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJN, et al. Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy. Stem Cells Translational Med. 2013;2(4):274\u201383.","journal-title":"Stem Cells Translational Med"},{"issue":"2","key":"4389_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018;23(2):181\u2013. \u2013\u200992.e5.","journal-title":"Cell Stem Cell"},{"issue":"11","key":"4389_CR31","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/sj.leu.2403524","volume":"18","author":"JR Passweg","year":"2004","unstructured":"Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, K\u00fchne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18(11):1835\u20138.","journal-title":"Leukemia"},{"issue":"4","key":"4389_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem cells translational Med. 2013;2(4):274\u201383.","journal-title":"Stem cells translational Med"},{"key":"4389_CR33","doi-asserted-by":"crossref","unstructured":"Liu E, Banerjee DMP, Macapinlac H, Thompson P, Ba\u015far R. Lucila Nassif kerbauy, Bethany J Overman, P. Thall, Mecit Kaplan, Vandana Nandivada, I. Kaur, A. N. Nunez Cortes, K. Cao, M. Daher, C. Hosing, E. Cohen, P. Kebriaei, R. Mehta, S. Neela. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine. 2020.","DOI":"10.1056\/NEJMoa1910607"},{"issue":"1","key":"4389_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"67","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67(1):165\u201383.","journal-title":"Annu Rev Med"},{"issue":"11","key":"4389_CR35","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","volume":"7","author":"T Anagnostou","year":"2020","unstructured":"Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7(11):e816\u201326.","journal-title":"Lancet Haematol"},{"issue":"8","key":"4389_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"4389_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181\u201392. e5.","journal-title":"Cell Stem Cell"},{"key":"4389_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","volume":"20","author":"DS Allan","year":"2021","unstructured":"Allan DS, Chakraborty M, Waller GC, Hochman MJ, Poolcharoen A, Reger RN, et al. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Mol Therapy Methods Clin Dev. 2021;20:559\u201371.","journal-title":"Mol Therapy Methods Clin Dev"},{"key":"4389_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","volume":"6","author":"M Carlsten","year":"2015","unstructured":"Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266.","journal-title":"Front Immunol"},{"issue":"6","key":"4389_CR40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"3","key":"4389_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"issue":"2","key":"4389_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"2","key":"4389_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell. 2020;27(2):224\u201337. e6.","journal-title":"Cell Stem Cell"},{"issue":"7643","key":"4389_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137.","journal-title":"Nature"},{"issue":"12","key":"4389_CR45","doi-asserted-by":"publisher","first-page":"e13727","DOI":"10.1111\/cpr.13727","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang M, Shen X, Xia C, Hu F, Huang D, et al. Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals. Cell Prolif. 2024;57(12):e13727.","journal-title":"Cell Prolif"},{"issue":"1","key":"4389_CR46","doi-asserted-by":"publisher","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","volume":"9","author":"L Herrera","year":"2019","unstructured":"Herrera L, Santos S, Vesga M, Anguita J, Martin-Ruiz I, Carrascosa T, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019;9(1):18729.","journal-title":"Sci Rep"},{"key":"4389_CR47","doi-asserted-by":"crossref","unstructured":"Stern LA, Jonsson VD, Priceman SJ. CAR T cell therapy progress and challenges for solid tumors. Tumor Microenvironment. 2020:297\u2013326.","DOI":"10.1007\/978-3-030-38862-1_11"},{"issue":"10","key":"4389_CR48","doi-asserted-by":"publisher","first-page":"e26527","DOI":"10.4161\/onci.26527","volume":"2","author":"L Boissel","year":"2013","unstructured":"Boissel L, Betancur M, Lu W, Krause D, Van Etten R, Wels W, et al. Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology. 2013;2(10):e26527.","journal-title":"Oncoimmunology"},{"issue":"6","key":"4389_CR49","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/trf.14564","volume":"58","author":"SM Williams","year":"2018","unstructured":"Williams SM, Sumstad D, Kadidlo D, Curtsinger J, Luo X, Miller JS, et al. Clinical-scale production of cGMP compliant CD3\/CD19 cell\u2010depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion. 2018;58(6):1458\u201367.","journal-title":"Transfusion"},{"issue":"Supplement1","key":"4389_CR50","doi-asserted-by":"publisher","first-page":"14607","DOI":"10.4049\/jimmunol.210.Supp.146.07","volume":"210","author":"E Badami","year":"2023","unstructured":"Badami E, Bus\u00e0 R, Gallina A, Iannolo G, Amico G, Douradinha B, et al. Fourth generation Glypican-3\u2013specific CAR-NK cells co-secreting IL-15 and IFN-\u03b1 have increased anti-tumor function versus hepatocellular carcinoma. J Immunol. 2023;210(Supplement1):14607\u201307.","journal-title":"J Immunol"},{"key":"4389_CR51","doi-asserted-by":"publisher","first-page":"1485461","DOI":"10.3389\/fimmu.2024.1485461","volume":"15","author":"I Kutle","year":"2024","unstructured":"Kutle I, Polten R, Stalp JL, Hachenberg J, Todzey F, Hass R, et al. Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. Front Immunol. 2024;15:1485461.","journal-title":"Front Immunol"},{"key":"4389_CR52","doi-asserted-by":"publisher","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","volume":"14","author":"B He","year":"2023","unstructured":"He B, Mai Q, Pang Y, Deng S, He Y, Xue R, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442.","journal-title":"Front Immunol"},{"issue":"6","key":"4389_CR53","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1073\/pnas.0813192106","volume":"106","author":"MA Cooper","year":"2009","unstructured":"Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009;106(6):1915\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"4389_CR54","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012;120(24):4751\u201360.","journal-title":"Blood"},{"key":"4389_CR55","doi-asserted-by":"publisher","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","volume":"14","author":"B He","year":"2023","unstructured":"He B, Mai Q, Pang Y, Deng S, He Y, Xue R, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442.","journal-title":"Front Immunol"},{"issue":"4","key":"4389_CR56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274\u201383.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"4389_CR57","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652\u20138.","journal-title":"Leukemia"},{"key":"4389_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv375","author":"C Zhang","year":"2016","unstructured":"Zhang C, Burger MC, Jennewein L, Gen\u00dfler S, Sch\u00f6nfeld K, Zeiner P, et al. ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv375.","journal-title":"J Natl Cancer Inst"},{"key":"4389_CR59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146\u201353.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"4389_CR60","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","volume":"27","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. Cell Stem Cell. 2020;27(2):224\u2013. \u2013\u200937.e6.","journal-title":"Cell Stem Cell"},{"issue":"16","key":"4389_CR61","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"4","key":"4389_CR62","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652\u20138.","journal-title":"Leukemia"},{"key":"4389_CR63","doi-asserted-by":"crossref","unstructured":"Hermanson DLKD. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 2015.","DOI":"10.3389\/fimmu.2015.00195"},{"key":"4389_CR64","doi-asserted-by":"crossref","unstructured":"Irving BAWA. The cytoplasmic domain of the T cell receptor zeta chain is sufcient to couple to receptor-associated signal transduction pathways. Cell. 1991.","DOI":"10.1016\/0092-8674(91)90314-O"},{"issue":"5","key":"4389_CR65","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor \u03b6 chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64(5):891\u2013901.","journal-title":"Cell"},{"issue":"26","key":"4389_CR66","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561\u20139.","journal-title":"N Engl J Med"},{"issue":"19","key":"4389_CR67","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","volume":"23","author":"L Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez L, Metais J-Y, Escudero A, Vela M, Valent\u00edn J, Vallcorba I, et al. Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. Clin Cancer Res. 2017;23(19):5824\u201335.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4389_CR68","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat reviews Clin Oncol. 2016;13(6):370\u201383.","journal-title":"Nat reviews Clin Oncol"},{"key":"4389_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omto.2022.06.003","volume":"26","author":"S Li","year":"2022","unstructured":"Li S, Zhao R, Zheng D, Qin L, Cui Y, Li Y, et al. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Mol Ther Oncolytics. 2022;26:15\u201326.","journal-title":"Mol Ther Oncolytics"},{"key":"4389_CR70","doi-asserted-by":"publisher","first-page":"893124","DOI":"10.3389\/fonc.2022.893124","volume":"12","author":"C Wei","year":"2022","unstructured":"Wei C, Xia K, Xie Y, Ye S, Ding Y, Liu Z, et al. Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells. Front Oncol. 2022;12:893124.","journal-title":"Front Oncol"},{"key":"4389_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omto.2022.06.003","volume":"26","author":"S Li","year":"2022","unstructured":"Li S, Zhao R, Zheng D, Qin L, Cui Y, Li Y, et al. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Mol Therapy - Oncolytics. 2022;26:15\u201326.","journal-title":"Mol Therapy - Oncolytics"},{"issue":"4","key":"4389_CR72","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"3","key":"4389_CR73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","volume":"30","author":"S Gill","year":"2016","unstructured":"Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016;30(3):157\u201367.","journal-title":"Blood Rev"},{"key":"4389_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.10.003","author":"SMM Gill","year":"2016","unstructured":"Gill SMM, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016. https:\/\/doi.org\/10.1016\/j.blre.2015.10.003.","journal-title":"Blood Rev"},{"key":"4389_CR75","doi-asserted-by":"crossref","unstructured":"Ramos CAHH, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016.","DOI":"10.1146\/annurev-med-051914-021702"},{"key":"4389_CR76","doi-asserted-by":"crossref","unstructured":"Jain MDDM. Concise review: emerging principles from the clini cal application of chimeric antigen receptor T cell therapies for B cell malignancies. Stem Cells. 2018.","DOI":"10.1002\/stem.2715"},{"key":"4389_CR77","doi-asserted-by":"crossref","unstructured":"Colamartino AB, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Remon JS et al. Efficient and robust NK-Cell transduction with Baboon Envelope pseudotyped lentivector: a major tool for immunotherapy. bioRxiv. 2019:625285.","DOI":"10.1101\/625285"},{"issue":"4","key":"4389_CR78","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, Van Steenbergen S, Van Elzakker P, Van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"key":"4389_CR79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omto.2022.06.003","volume":"26","author":"S Li","year":"2022","unstructured":"Li S, Zhao R, Zheng D, Qin L, Cui Y, Li Y, et al. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Mol Ther Oncolytics. 2022;26:15\u201326.","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"4389_CR80","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"4389_CR81","volume":"2018","author":"S Matosevic","year":"2018","unstructured":"Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018;2018(1):4054815.","journal-title":"J Immunol Res"},{"key":"4389_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4054815","author":"S Matosevic","year":"2018","unstructured":"Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. Journal of Immunology Research. 2018. https:\/\/doi.org\/10.1155\/2018\/4054815.","journal-title":"Journal of Immunology Research"},{"issue":"1","key":"4389_CR83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Hunzeker JT, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Mol Ther. 2020;28(1):52\u201363.","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"4389_CR84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/hum.2019.220","volume":"31","author":"P Tornabene","year":"2020","unstructured":"Tornabene P, Trapani I. Can adeno-associated viral vectors deliver effectively large genes? Hum Gene Ther. 2020;31(1\u20132):47\u201356.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"4389_CR85","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"12","key":"4389_CR86","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s43018-022-00476-w","volume":"3","author":"L Brunello","year":"2022","unstructured":"Brunello L. Avoiding CAR-NK cell fratricide. Nat Cancer. 2022;3(12):1445.","journal-title":"Nat Cancer"},{"issue":"3","key":"4389_CR87","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"issue":"9","key":"4389_CR88","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s00262-023-03374-x","volume":"72","author":"J Pfeifer Serrahima","year":"2023","unstructured":"Pfeifer Serrahima J, Zhang C, Oberoi P, Bodden M, R\u00f6der J, Arndt C, et al. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers. Cancer Immunology, Immunotherapy. 2023;72(9):2905\u201318.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"4389_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.893124","volume":"12","author":"C Wei","year":"2022","unstructured":"Wei C, Xia K, Xie Y, Ye S, Ding Y, Liu Z, et al. Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D (bbz) CAR-T cells. Frontiers in Oncology. 2022;12:893124.","journal-title":"Frontiers in Oncology"},{"issue":"45","key":"4389_CR90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107507118","volume":"118","author":"J Wang","year":"2021","unstructured":"Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Bernal-Crespo V, et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proceedings of the National Academy of Sciences. 2021;118(45):e2107507118.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"4389_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003050","author":"CI Jan","year":"2021","unstructured":"Jan CI, Huang SW, Canoll P, Bruce JN, Lin YC, Pan CM, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003050.","journal-title":"J Immunother Cancer"},{"issue":"47","key":"4389_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add1187","volume":"8","author":"WN Liu","year":"2022","unstructured":"Liu WN, So WY, Harden SL, Fong SY, Wong MXY, Tan WWS, et al. Successful targeting of PD-1\/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model. Sci Adv. 2022;8(47):eadd1187.","journal-title":"Sci Adv"},{"issue":"1","key":"4389_CR93","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12885-025-13780-2","volume":"25","author":"L Zhi","year":"2025","unstructured":"Zhi L, Zhang Z, Gao Q, Shang C, He W, Wang Y, et al. CAR-NK cells with dual targeting of PD-L1 and MICA\/B in lung cancer tumor models. BMC Cancer. 2025;25(1):337.","journal-title":"BMC Cancer"},{"issue":"9","key":"4389_CR94","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s00262-023-03374-x","volume":"72","author":"J Pfeifer Serrahima","year":"2023","unstructured":"Pfeifer Serrahima J, Zhang C, Oberoi P, Bodden M, R\u00f6der J, Arndt C, et al. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers. Cancer Immunol Immunother. 2023;72(9):2905\u201318.","journal-title":"Cancer Immunol Immunother"},{"key":"4389_CR95","volume-title":"Childs. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","author":"D Allan","year":"2021","unstructured":"Allan D, Giacomo MC, Waller C, Hochman MJ, Poolcharoen A, Reger R. R. Childs. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Molecular Therapy: Methods & Clinical Development; 2021."},{"issue":"12","key":"4389_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13727","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang M, Shen X, Xia C, Hu F, Huang D, et al. Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals. Cell Prolif. 2024;57(12):e13727.","journal-title":"Cell Prolif"},{"issue":"11","key":"4389_CR97","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","volume":"33","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei P, Izsv\u00e1k Z, Narayanavari SA, Singh H, Ivics Z. Gene therapy with the sleeping beauty transposon system. Trends Genet. 2017;33(11):852\u201370.","journal-title":"Trends Genet"},{"key":"4389_CR98","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gde.2018.06.003","volume":"52","author":"M Hudecek","year":"2018","unstructured":"Hudecek M, Ivics Z. Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. Current opinion in genetics & development. 2018;52:100\u20138.","journal-title":"Current opinion in genetics & development"},{"issue":"6","key":"4389_CR99","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Molecular Therapy. 2019;27(6):1114\u201325.","journal-title":"Molecular Therapy"},{"key":"4389_CR100","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S500520","author":"X Pan","year":"2025","unstructured":"Pan X, Zhang Y-W-Q, Dai C, Zhang J, Zhang M, Chen X. Applications of mRNA delivery in cancer immunotherapy. International Journal of Nanomedicine. 2025. https:\/\/doi.org\/10.2147\/IJN.S500520.","journal-title":"International Journal of Nanomedicine"},{"key":"4389_CR101","doi-asserted-by":"crossref","unstructured":"Craddock JALA, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafcking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010.","DOI":"10.1097\/CJI.0b013e3181ee6675"},{"key":"4389_CR102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-1183","author":"MHWJ Kershaw","year":"2006","unstructured":"Kershaw MHWJ, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006. https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1183.","journal-title":"Clin Cancer Res"},{"key":"4389_CR103","doi-asserted-by":"crossref","unstructured":"Lamers CHSS, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Therapy. 2013.","DOI":"10.1038\/mt.2013.17"},{"key":"4389_CR104","doi-asserted-by":"crossref","unstructured":"Steven Feins WK, Williams E, Milone M, Fraietta J. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J hematology\/oncology. 2019.","DOI":"10.1002\/ajh.25418"},{"key":"4389_CR105","doi-asserted-by":"crossref","unstructured":"Ali Sayadmanesh VY, Valizadeh A, Abedelahi A, Shafaei H, Shanehbandi D, Basiri M. B. Baradaran. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer. Int Immunopharmacol. 2023.","DOI":"10.1016\/j.intimp.2023.111093"},{"key":"4389_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25445","author":"AVTC Hirayama","year":"2019","unstructured":"Hirayama AVTC. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019. https:\/\/doi.org\/10.1002\/ajh.25445.","journal-title":"Am J Hematol"},{"key":"4389_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.125","author":"YTZ Hu","year":"2018","unstructured":"Hu YTZ, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018. https:\/\/doi.org\/10.1038\/aps.2017.125.","journal-title":"Acta Pharmacol Sin"},{"key":"4389_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11","author":"CLJH Bonifant","year":"2016","unstructured":"Bonifant CLJH, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy - Oncolytics. 2016. https:\/\/doi.org\/10.1038\/mto.2016.11.","journal-title":"Molecular Therapy - Oncolytics"},{"key":"4389_CR109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","author":"DWGR Lee","year":"2014","unstructured":"Lee DWGR, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"4389_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.01.008","author":"DSJCM Allan","year":"2021","unstructured":"Allan DSJCM, Waller GC, Hochman MJ, Poolcharoen A, Reger RN, et al. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Molecular Therapy. 2021. https:\/\/doi.org\/10.1016\/j.omtm.2021.01.008.","journal-title":"Molecular Therapy"},{"issue":"3","key":"4389_CR111","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","volume":"24","author":"MJ Osborn","year":"2016","unstructured":"Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases. Mol Ther. 2016;24(3):570\u201381.","journal-title":"Mol Ther"},{"key":"4389_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10070908","author":"JM Cronk","year":"2021","unstructured":"Cronk JM, Fafoutis E, Brown MG. Licensing Natural Killers for Antiviral Immunity. Pathogens. 2021. https:\/\/doi.org\/10.3390\/pathogens10070908.","journal-title":"Pathogens"},{"key":"4389_CR113","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-38862-1","author":"LAJV Stern","year":"2020","unstructured":"Stern LAJV, Priceman SJ. CAR T cell therapy progress and challenges for solid tumors. Cancer Treat Res. 2020. https:\/\/doi.org\/10.1007\/978-3-030-38862-1.","journal-title":"Cancer Treat Res"},{"key":"4389_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02406-6","author":"GMWM Robbins","year":"2021","unstructured":"Robbins GMWM, Pomeroy EJ, Moriarity BS. Nonviral Genome Engineering of Natural Killer Cells. Stem Cell Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13287-021-02406-6.","journal-title":"Stem Cell Res Ther"},{"key":"4389_CR115","unstructured":"Paul AA, *, Chrystal MP, *. Mojgan Ahmadzadeh *, Akg\u00fcl Akpinarli \u2020, Douglas C Palmer *, Noriko Sato \u2021, Andrew Kaiser *, Christian Heinrichs *, Christopher A Klebanoff \u00a7, Yutaka Tagaya \u2021, Nicholas P Restifo. Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. 2006."},{"key":"4389_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01238-x","author":"SYFT Wu","year":"2020","unstructured":"Wu SYFT, Jiang YZ, Shao ZM. Natural Killer Cells in Cancer Biology and Therapy. Mol Cancer. 2020. https:\/\/doi.org\/10.1186\/s12943-020-01238-x.","journal-title":"Mol Cancer"},{"key":"4389_CR117","unstructured":"Xingwang Zhu 1. Jieyun Xue 2,#, Hongzhou Jiang 3,#, Dongwei Xue 1,. CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside. 2024."},{"issue":"5","key":"4389_CR118","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","volume":"29","author":"YY Ng","year":"2022","unstructured":"Ng YY, Du Z, Zhang X, Chng WJ, Wang S. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. Cancer Gene Therapy. 2022;29(5):475\u201383.","journal-title":"Cancer Gene Therapy"},{"key":"4389_CR119","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000131","author":"F Li","year":"2020","unstructured":"Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000131.","journal-title":"J Immunother Cancer"},{"key":"4389_CR120","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","volume":"16","author":"YY Ng","year":"2020","unstructured":"Ng YY, Tay JCK, Wang S. CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts. Molecular Therapy - Oncolytics. 2020;16:75\u201385.","journal-title":"Molecular Therapy - Oncolytics"},{"key":"4389_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/cells13030246","author":"A Kiefer","year":"2024","unstructured":"Kiefer A, Pr\u00fcfer M, R\u00f6der J, Pfeifer Serrahima J, Bodden M, K\u00fchnel I, et al. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13030246.","journal-title":"Cells"},{"key":"4389_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457887","volume":"15","author":"J Pfeifer Serrahima","year":"2024","unstructured":"Pfeifer Serrahima J, Schoenfeld K, K\u00fchnel I, Harwardt J, Macarr\u00f3n Palacios A, Pr\u00fcfer M, et al. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2\/HER2-positive malignancies. Front Immunol. 2024;15:1457887.","journal-title":"Front Immunol"},{"issue":"2","key":"4389_CR123","doi-asserted-by":"publisher","first-page":"e20230047","DOI":"10.1002\/INMD.20230047","volume":"2","author":"K Qian","year":"2024","unstructured":"Qian K, Li G, Zhang S, Fu W, Li T, Zhao J, et al. CAR-T\u2010cell products in solid tumors: Progress, challenges, and strategies. Interdisciplinary Med. 2024;2(2):e20230047.","journal-title":"Interdisciplinary Med"},{"key":"4389_CR124","doi-asserted-by":"publisher","first-page":"1440764","DOI":"10.3389\/fimmu.2024.1440764","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xie J, Wu H, Huang J, Zheng D, Wang S, et al. NK cell based immunotherapy against oral squamous cell carcinoma. Front Immunol. 2024;15:1440764.","journal-title":"Front Immunol"},{"key":"4389_CR125","unstructured":"Liu YSSHKH-. CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors. 2025."},{"key":"4389_CR126","doi-asserted-by":"crossref","unstructured":"Weisheng Zhang YM, Feng X, Han Z. Mar. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 18 2022.","DOI":"10.1186\/s40364-022-00364-6"},{"key":"4389_CR127","doi-asserted-by":"crossref","unstructured":"Liu E, Marin D, Banerjee P et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. 2020.","DOI":"10.1056\/NEJMoa1910607"},{"key":"4389_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13:1\u201310.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4389_CR129","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","volume":"20","author":"G Roex","year":"2022","unstructured":"Roex G, Campillo-Davo D, Flumens D, Shaw PAG, Krekelbergh L, De Reu H, et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J translational Med. 2022;20(1):124.","journal-title":"J translational Med"},{"issue":"23","key":"4389_CR130","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1182\/blood.2022017794","volume":"140","author":"R Rahnama","year":"2022","unstructured":"Rahnama R, Bonifant CL. Engineering builds multipotency for iPSC-NKs. Blood. 2022;140(23):2414\u20136.","journal-title":"Blood"},{"issue":"10","key":"4389_CR131","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28(10):2133\u201344.","journal-title":"Nat Med"},{"issue":"5","key":"4389_CR132","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019;129(5):2094\u2013106.","journal-title":"J Clin Invest"},{"issue":"21","key":"4389_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112828","volume":"23","author":"G Ure\u00f1a-Bail\u00e9n","year":"2022","unstructured":"Ure\u00f1a-Bail\u00e9n G, Dobrowolski J-M, Hou Y, Dirlam A, Roig-Merino A, Schleicher S, et al. Preclinical evaluation of CRISPR-edited CAR-NK-92 cells for off-the-shelf treatment of AML and B-ALL. Int J Mol Sci. 2022;23(21):12828.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"4389_CR134","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.7150\/ijbs.64630","volume":"17","author":"B Cao","year":"2021","unstructured":"Cao B, Liu M, Huang J, Zhou J, Li J, Lian H, et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci. 2021;17(14):3850\u201361.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4389_CR135","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1186\/s12967-024-05851-y","volume":"22","author":"E Torchiaro","year":"2024","unstructured":"Torchiaro E, Cortese M, Petti C, Basirico\u2019 M, Invrea F, D\u2019Andrea A, et al. Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer. J Translational Med. 2024;22(1):1100.","journal-title":"J Translational Med"},{"issue":"Supplement 1","key":"4389_CR136","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/blood-2024-204369","volume":"144","author":"J Jang","year":"2024","unstructured":"Jang J, Stanojevic M, Piccinelli S, Sheffer M, Birch GC, Shapiro RM, et al. Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia. Blood. 2024;144(Supplement 1):917.","journal-title":"Blood"},{"key":"4389_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1485461","author":"I Kutle","year":"2024","unstructured":"Kutle I, Polten R, Stalp JL, Hachenberg J, Todzey F, Hass R, et al. Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. Frontiers in Immunology. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1485461.","journal-title":"Frontiers in Immunology"},{"key":"4389_CR138","doi-asserted-by":"crossref","unstructured":"Lasse Vedel. J\u00f8rgensen 1, #, Emil Birch Christensen 1,2,#, Mike Bogetofte Barnkob 1,2, Torben Barington 1,2. The clinical landscape of CAR NK cells. 2025.","DOI":"10.1186\/s40164-025-00633-8"},{"issue":"1","key":"4389_CR139","doi-asserted-by":"publisher","first-page":"e0317401","DOI":"10.1371\/journal.pone.0317401","volume":"20","author":"L Yang","year":"2025","unstructured":"Yang L, Pham K, Xi Y, Wu Q, Liu D, Robertson KD, et al. Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PLoS ONE. 2025;20(1):e0317401.","journal-title":"PLoS ONE"},{"issue":"12Supplement","key":"4389_CR140","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1158\/1538-7445.AM2022-5185","volume":"82","author":"K Harano","year":"2022","unstructured":"Harano K, Kaneko S, Nakatsura T, Yuda J, Fuse N, Sato A, et al. Abstract 5185: First in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination. Cancer Res. 2022;82(12Supplement):5185.","journal-title":"Cancer Res"},{"key":"4389_CR141","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","volume":"23","author":"Z Du","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S. piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Ther Methods Clin Dev. 2021;23:582\u201396.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"4389_CR142","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"A Leivas","year":"2021","unstructured":"Leivas A, Valeri A, C\u00f3rdoba L, Garc\u00eda-Ortiz A, Ortiz A, S\u00e1nchez-Vega L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11(8):146.","journal-title":"Blood Cancer J"},{"issue":"7","key":"4389_CR143","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/ijc.32269","volume":"145","author":"S Oelsner","year":"2019","unstructured":"Oelsner S, Waldmann A, Billmeier A, R\u00f6der J, Lindner A, Ullrich E, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int J Cancer. 2019;145(7):1935\u201345.","journal-title":"Int J Cancer"},{"issue":"20","key":"4389_CR144","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1182\/bloodadvances.2022007405","volume":"7","author":"AG Mansour","year":"2023","unstructured":"Mansour AG, Teng K-Y, Li Z, Zhu Z, Chen H, Tian L, et al. Off-the-shelf CAR\u2013engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023;7(20):6225\u201339.","journal-title":"Blood Adv"},{"issue":"4","key":"4389_CR145","doi-asserted-by":"publisher","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","volume":"5","author":"S Gen\u00dfler","year":"2016","unstructured":"Gen\u00dfler S, Burger MC, Zhang C, Oelsner S, Mildenberger I, Wagner M, et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2016;5(4):e1119354.","journal-title":"Oncoimmunology"},{"issue":"8","key":"4389_CR146","doi-asserted-by":"publisher","first-page":"e12858","DOI":"10.1111\/cpr.12858","volume":"53","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zhou Y, Huang K-H, Fang X, Li Y, Wang F, et al. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. Cell Prolif. 2020;53(8):e12858.","journal-title":"Cell Prolif"},{"key":"4389_CR147","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv375","author":"C Zhang","year":"2015","unstructured":"Zhang C, Burger MC, Jennewein L, Gen\u00dfler S, Sch\u00f6nfeld K, Zeiner P, et al. ErbB2\/HER2-Specific NK cells for targeted therapy of glioblastoma. JNCI: Journal of the National Cancer Institute. 2015. https:\/\/doi.org\/10.1093\/jnci\/djv375.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"2","key":"4389_CR148","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Sch\u00f6nfeld","year":"2015","unstructured":"Sch\u00f6nfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, et al. Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2\/HER2-Specific Chimeric Antigen Receptor. Mol Ther. 2015;23(2):330\u20138.","journal-title":"Mol Ther"},{"key":"4389_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228894","author":"C Heim","year":"2023","unstructured":"Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, et al. ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma. Frontiers in Immunology. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1228894.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"4389_CR150","doi-asserted-by":"publisher","first-page":"e1250050","DOI":"10.1080\/2162402X.2016.1250050","volume":"6","author":"S Kailayangiri","year":"2017","unstructured":"Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, et al. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology. 2017;6(1):e1250050.","journal-title":"Oncoimmunology"},{"issue":"3","key":"4389_CR151","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","volume":"16","author":"R Esser","year":"2012","unstructured":"Esser R, M\u00fcller T, Stefes D, Kloess S, Seidel D, Gillies SD, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med. 2012;16(3):569\u201381.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4389_CR152","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9(1):64\u201378.","journal-title":"Am J Cancer Res"},{"issue":"35","key":"4389_CR153","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016;7(35):56219\u201332.","journal-title":"Oncotarget"},{"issue":"4","key":"4389_CR154","first-page":"410","volume":"20","author":"M Asadi","year":"2023","unstructured":"Asadi M, Kiani R, Razban V, Faraji SN, Ahmadi A, Fallahi J, et al. Harnessing the Power of CAR-NK Cells: A Promising Off-the-Shelf Therapeutic Strategy for CD38-Positive Malignancies. Iran J Immunol. 2023;20(4):410\u201326.","journal-title":"Iran J Immunol"},{"issue":"3","key":"4389_CR155","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"issue":"5","key":"4389_CR156","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrg.2016.28","volume":"17","author":"SQ Tsai","year":"2016","unstructured":"Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet. 2016;17(5):300\u201312.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"4389_CR157","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24(6):1012\u20139.","journal-title":"Genome Res"},{"issue":"33","key":"4389_CR158","doi-asserted-by":"publisher","first-page":"10437","DOI":"10.1073\/pnas.1512503112","volume":"112","author":"K Schumann","year":"2015","unstructured":"Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015;112(33):10437\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7714","key":"4389_CR159","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405\u20139.","journal-title":"Nature"},{"key":"4389_CR160","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","volume":"208","author":"X Liang","year":"2015","unstructured":"Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 2015;208:44\u201353.","journal-title":"J Biotechnol"},{"key":"4389_CR161","unstructured":"Xiaowen Tang 1 2 LY, Ansel Z. P Nalin 6, Haiping Dai 5 1 2, Ting Xu 5 1 2, Jia Yin 5 1 2, Fengtao You 2 3 4, Mingqing Zhu 5 1 2, Wenhong Shen 5 1 2, Guanghua Chen 5 1 2, Xiaming Zhu 5 1 2, Depei Wu 5 1 2, Jianhua Yu 6 7 8. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res Mol Cancer. 2018."},{"key":"4389_CR162","unstructured":"NCT02944162 Io. A Phase I Study of CD33-Directed Chimeric Antigen Receptor (CAR) Modified NK-92 Cells in Patients With Relapsed or Refractory Acute Myeloid 2018 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02944162"},{"key":"4389_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.03.011","author":"LCD Xiao","year":"2019","unstructured":"Xiao LCD, Gan H, Sun Y, Huang N, Xiong H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019. https:\/\/doi.org\/10.1016\/j.ymthe.2019.03.011.","journal-title":"Mol Ther"},{"issue":"6","key":"4389_CR164","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8(6):1083\u20139.","journal-title":"Am J Cancer Res"},{"key":"4389_CR165","unstructured":"ClinicalTrials.gov. 19 Clinical Trials Associated with CAR-NK Cells. 2025."},{"key":"4389_CR166","unstructured":"A Phase I Study of CD33-Directed Chimeric Antigen Receptor. (CAR) Modified NK-92 Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Journal of Hematology & Oncology; 2020."},{"key":"4389_CR167","unstructured":"Frankfurt UH. Phase I Clinical Trial of Intracranial Injection of HER2-Targeted CAR-NK Cells in Patients with Recurrent Glioblastoma (CAR2BRAIN). 2025."},{"key":"4389_CR168","doi-asserted-by":"crossref","unstructured":"Frank Cichocki BG, Jeffrey S. Aug. Miller. Human NK Cell Development: One Road or Many? Frontiers in Immunology. 29 2019.","DOI":"10.3389\/fimmu.2019.02078"},{"issue":"3","key":"4389_CR169","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol Res. 2019;7(3):363\u201375.","journal-title":"Cancer Immunol Res"},{"key":"4389_CR170","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-134625","volume":"136","author":"C Bachier","year":"2020","unstructured":"Bachier C, Borthakur G, Hosing C, Blum W, Rotta M, Ojeras P, et al. A phase 1 study of NKX101, an allogeneic CAR natural killer (NK) cell therapy, in subjects with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS). Blood. 2020;136:42\u20133.","journal-title":"Blood"},{"issue":"2","key":"4389_CR171","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/77793","volume":"1","author":"A Diefenbach","year":"2000","unstructured":"Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1(2):119\u201326.","journal-title":"Nat Immunol"},{"key":"4389_CR172","unstructured":"Maria Karvouni 1 MV-M, Katharina H Susek 1, Alamdar Hussain 1, Mari Gilljam 1, Yanliang Zhang 2, Dixon Gray J. 2, Johan Lund 1, Gunnar Kaufmann 2, Hans-Gustaf Ljunggren 3, Henry Ji 2, Andreas Lundqvist 4, Arnika K Wagner 1, Wenzhong Guo 2, Evren Alici. Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide. Cytotherapy Mol Cancer. 2023."},{"key":"4389_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975.","journal-title":"EBioMedicine"},{"issue":"1","key":"4389_CR174","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1186\/s12885-025-14837-y","volume":"25","author":"M Bakhtiyaridovvombaygi","year":"2025","unstructured":"Bakhtiyaridovvombaygi M, Kheyrandish S, Safdari SM, Eskandrian S, Rousta H, Hossaini D, et al. A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy. BMC Cancer. 2025;25(1):1461.","journal-title":"BMC Cancer"},{"key":"4389_CR175","doi-asserted-by":"crossref","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol. 2024;Volume 15\u20132024.","DOI":"10.3389\/fimmu.2024.1454427"},{"issue":"10","key":"4389_CR176","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"4389_CR177","doi-asserted-by":"publisher","first-page":"108212","DOI":"10.1016\/j.biotechadv.2023.108212","volume":"68","author":"C Hinnekens","year":"2023","unstructured":"Hinnekens C, De Smedt SC, Fraire JC, Braeckmans K. Non-viral engineering of NK cells. Biotechnol Adv. 2023;68:108212.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"4389_CR178","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean EM, McCarthy HO. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J Nanobiotechnol. 2024;22(1):552.","journal-title":"J Nanobiotechnol"},{"key":"4389_CR179","doi-asserted-by":"crossref","unstructured":"Petri K, Ferrari S, Cianciotti BC. Safety and efficacy of CRISPR\/Cas-based genome editing tools: applications and considerations in cell and gene therapy. Frontiers Media SA; 2026. p. 1809809.","DOI":"10.3389\/fimmu.2026.1809809"},{"issue":"3","key":"4389_CR180","doi-asserted-by":"publisher","first-page":"102636","DOI":"10.1016\/j.omtn.2025.102636","volume":"36","author":"N Kalter","year":"2025","unstructured":"Kalter N, Fuster-Garc\u00eda C, Silva A, Ronco-D\u00edaz V, Roncelli S, Turchiano G, et al. Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges. Mol Therapy Nucleic Acids. 2025;36(3):102636.","journal-title":"Mol Therapy Nucleic Acids"},{"key":"4389_CR181","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","volume":"11","author":"MA Morgan","year":"2020","unstructured":"Morgan MA, B\u00fcning H, Sauer M, Schambach A. Use of cell and genome modification technologies to generate improved off-the-shelf CAR T and CAR NK cells. Front Immunol. 2020;11:1965.","journal-title":"Front Immunol"},{"issue":"5","key":"4389_CR182","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/mps8050102","volume":"8","author":"S Khanal","year":"2025","unstructured":"Khanal S, Bhattarai N. A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells. Methods Protocols. 2025;8(5):102.","journal-title":"Methods Protocols"},{"issue":"4","key":"4389_CR183","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3343\/alm.2023.0382","volume":"44","author":"NK Lee","year":"2024","unstructured":"Lee NK, Chang JW. Manufacturing cell and gene therapies: challenges in clinical translation. Ann Lab Med. 2024;44(4):314\u201323.","journal-title":"Ann Lab Med"},{"key":"4389_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.02.022","author":"B Fury","year":"2025","unstructured":"Fury B, Bauer G. GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forward. Molecular Therapy. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.022.","journal-title":"Molecular Therapy"},{"key":"4389_CR185","unstructured":"Antonio Valeri 1. Almudena Garc\u00eda-Ortiz 1,2, Eva Castellano 1,2, Laura C\u00f3rdoba 1,2, Elena Maroto-Mart\u00edn 1,2, Jessica Encinas 1,2, Alejandra Leivas 1,2, Paula R\u00edo 3, Joaqu\u00edn Mart\u00ednez-L\u00f3pez Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022."},{"key":"4389_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953849","volume":"13","author":"A Valeri","year":"2022","unstructured":"Valeri A, Garc\u00eda-Ortiz A, Castellano E, C\u00f3rdoba L, Maroto-Mart\u00edn E, Encinas J, et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022;13:953849.","journal-title":"Front Immunol"},{"key":"4389_CR187","unstructured":"Antonio Valeri 1 2 AG-O. Eva Castellano 1 2, Laura C\u00f3rdoba 1 2, Elena Maroto-Mart\u00edn 1 2, Jessica Encinas 1 2, Alejandra Leivas 1 2, Paula R\u00edo 3, Joaqu\u00edn Mart\u00ednez-L\u00f3pez. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022."},{"issue":"1","key":"4389_CR188","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE. 2012;7(1):e30264.","journal-title":"PLoS ONE"},{"issue":"9","key":"4389_CR189","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/eji.201948375","volume":"50","author":"XY Zhao","year":"2020","unstructured":"Zhao XY, Jiang Q, Jiang H, Hu LJ, Zhao T, Yu XX, et al. Expanded clinical-grade membrane-bound IL-21\/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol. 2020;50(9):1374\u201385.","journal-title":"Eur J Immunol"},{"key":"4389_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953849","author":"A Valeri","year":"2022","unstructured":"Valeri A, Garc\u00eda-Ortiz A, Castellano E, et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Frontiers in Immunology. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.953849.","journal-title":"Frontiers in Immunology"},{"key":"4389_CR191","doi-asserted-by":"crossref","unstructured":"Markus Granzin 1 AS. Matthias Miller 2, Richard Childs 3, Volker Huppert 4, Adelheid Cerwenka Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology. 2016.","DOI":"10.1080\/2162402X.2016.1219007"},{"key":"4389_CR192","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4797","author":"C Imai","year":"2005","unstructured":"Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005. https:\/\/doi.org\/10.1182\/blood-2004-12-4797.","journal-title":"Blood"},{"key":"4389_CR193","doi-asserted-by":"crossref","unstructured":"Oscar Fabian Garcia-Aponte 1 CH., Bence Kozma. Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy. J Biol Eng. 2021.","DOI":"10.1186\/s13036-021-00264-7"},{"key":"4389_CR194","unstructured":"Sen Xu 1 JG. Rubin Jiang 1, Hao Chen. Bioreactor productivity and media cost comparison for different intensified cell culture processes. Biotechnol Prog. 2017."},{"key":"4389_CR195","doi-asserted-by":"crossref","unstructured":"Abdulla Berjis DM, Oscar A, Aguilar O, Pomp O, Johnson AV, Finck NW, Engel L, Chen N, Plachta J, Scholler LL, Lanier CH, June. & Neil C. Sheppard Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat Commun volume. 2024.","DOI":"10.1038\/s41467-024-47574-0"},{"key":"4389_CR196","unstructured":"Challener CA. Challenges to Cell Expansion for Allogenic Cell Therapies. BioPharm Int. 2023."},{"key":"4389_CR197","doi-asserted-by":"crossref","unstructured":"Adam Joules 1 ASM. Troy Louwagie 2, Guanglin Yu 2, Allison Hubel Probing mechanisms of cryopreservation damage to natural killer cells. Cytotherapy. 2025.","DOI":"10.1016\/j.jcyt.2025.01.012"},{"key":"4389_CR198","doi-asserted-by":"crossref","unstructured":"Jennifer N, Saultz 1 FO. Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. Front Immunol Mol Cancer. 2023.","DOI":"10.3389\/fimmu.2023.1304689"},{"key":"4389_CR199","doi-asserted-by":"crossref","unstructured":"Gaby D, Lizana-Vasquez. 1, Madeline Torres-Lugo 1, R Brent Dixon 2,3, John D Powderly II 2,3, Renaud F Warin. The application of autologous cancer immunotherapies in the age of memory-NK cells. Front Immunol Mol Cancer. 2023.","DOI":"10.3389\/fimmu.2023.1167666"},{"key":"4389_CR200","doi-asserted-by":"crossref","unstructured":"Pol P\u00e9rez-Rubio. 1, \u2217, Jes\u00fas Lavado-Garc\u00eda 1,2,3, Laia Bosch-Molist 1, Elianet Lorenzo Romero 1, Laura Cervera 1, Francesc G\u00f2dia Extracellular vesicle depletion and UGCG overexpression mitigate the cell density effect in HEK293 cell culture transfection. Mol Ther Methods Clin Dev. 2024.","DOI":"10.1016\/j.omtm.2024.101190"},{"key":"4389_CR201","unstructured":"Changjiang Guo 1 HC, Lu JYH, Xia Q, Li X, Guo X. Tong Wang,Lingtong Zhi, Zhiyuan Niu, Wuling Zhu. Engagement of an optimized lentiviral vector enhances the expression and cytotoxicity of CAR in human NK cells. Mol Immunol. 2023."},{"key":"4389_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55239-y","author":"LSS Herrera","year":"2019","unstructured":"Herrera LSS, Vesga MA, Anguita J, Martin-Ruiz I, Carrascosa T, et al. Adult Peripheral Blood and Umbilical Cord Blood NK Cells Are Good Sources for Effective CAR Therapy Against CD19 Positive Leukemic Cells. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/s41598-019-55239-y.","journal-title":"Sci Rep"},{"key":"4389_CR203","doi-asserted-by":"crossref","unstructured":"Elena L. Aronovich 1, R Scott McIvor 1, Perry B Hackett. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet. 2011.","DOI":"10.1093\/hmg\/ddr140"},{"key":"4389_CR204","doi-asserted-by":"crossref","unstructured":"Jawad Fares ZBD, Julian S, Rechberger SA, Toll JD, Schwartz DJ, Daniels JS. Miller & Soumen Khatua. Advances in NK cell therapy for brain tumors. 2023.","DOI":"10.1038\/s41698-023-00356-1"},{"issue":"5","key":"4389_CR205","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050748","volume":"13","author":"K Ma","year":"2023","unstructured":"Ma K, Zheng Z-R, Meng Y. Natural killer cells, as the rising point in tissues, are forgotten in the kidney. Biomolecules. 2023;13(5):748.","journal-title":"Biomolecules"},{"key":"4389_CR206","unstructured":"LL L. NK cell recognition. Annu Rev Immunol. 2005."},{"key":"4389_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.01.022","author":"PRC Dogra","year":"2020","unstructured":"Dogra PRC, Ma W, Toth M, Senda T, Carpenter DJ, et al. Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell. 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.01.022.","journal-title":"Cell"},{"key":"4389_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626098","author":"EAS Liu","year":"2021","unstructured":"Liu EAS, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, et al. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Frontiers in Immunology. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.626098.","journal-title":"Frontiers in Immunology"},{"key":"4389_CR209","unstructured":"Antonio Valeri1 AG-O. Almudena Garc\u00eda-Ortiz1,2Eva Castellano,Eva Castellano1,2Laura C rdoba,Laura C\u00f3rdoba1,2Elena Maroto-Mart\u00edn,Elena Maroto-Mart\u00edn1,2Jessica Encinas,Jessica Encinas1,2Alejandra Leivas,Alejandra Leivas1,2Paula R\u00edoPaula R\u00edo3Joaqu\u00edn Mart\u00ednez-L pez,*Joaqu\u00edn Mart\u00ednez-L\u00f3pez1,2*. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol. 2022."},{"key":"4389_CR210","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121606","author":"MH Shin","year":"2023","unstructured":"Shin MH, Oh E, Kim Y, Nam D-H, Jeon SY, Yu JH, et al. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12121606.","journal-title":"Cells"},{"issue":"10","key":"4389_CR211","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"4389_CR212","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115899","volume":"22","author":"E Wrona","year":"2021","unstructured":"Wrona E, Borowiec M, Potemski P. CAR-NK cells in the treatment of solid tumors. Int J Mol Sci. 2021;22(11):5899.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4389_CR213","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1186\/s12967-024-05903-3","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q, et al. CAR-armored-cell therapy in solid tumor treatment. J Transl Med. 2024;22(1):1076.","journal-title":"J Transl Med"},{"key":"4389_CR214","doi-asserted-by":"crossref","unstructured":"Christian L, Flugel RGM, Giedre Krenciute G, Dotti SR, Riddell, Dimitrios L, Wagner. & Mohamed Abou-el-Enein. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Reviews Clin Oncol. 2023.","DOI":"10.1038\/s41571-022-00704-3"},{"key":"4389_CR215","unstructured":"Fang Lv XW, Jin Song P, Wang S, Ren W, Guo Q, Xue H, Zhang. & Jun Zhao. Single cell transcriptome revealed tumor associated antigen (TAA) profile in lung adenocarcinoma (LUAD). Biomark Res. 2021."},{"issue":"3","key":"4389_CR216","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41588-023-01313-1","volume":"55","author":"L Zapata","year":"2023","unstructured":"Zapata L, Caravagna G, Williams MJ, Lakatos E, AbdulJabbar K, Werner B, et al. Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors. Nat Genet. 2023;55(3):451\u201360.","journal-title":"Nat Genet"},{"key":"4389_CR217","unstructured":"Lei P. # 1 2 GS, Luojia Yang # 3 4 5 6, Liqun Zhou 3 4 5 7, Sidi Chen CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol Mol Cancer. 2024."},{"issue":"1","key":"4389_CR218","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1186\/s12967-024-05903-3","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q, et al. CAR-armored-cell therapy in solid tumor treatment. J Transl Med. 2024;22(1):1076.","journal-title":"J Transl Med"},{"issue":"7","key":"4389_CR219","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cancers9070092","volume":"9","author":"P Sridhar","year":"2017","unstructured":"Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers. 2017;9(7):92.","journal-title":"Cancers"},{"key":"4389_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.10.009","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Kluesner MG, Lahr WS, Smeester BA, Crosby MR, et al. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy. Mol Ther. 2020. https:\/\/doi.org\/10.1016\/j.ymthe.2019.10.009.","journal-title":"Mol Ther"},{"key":"4389_CR221","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05903-3","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yang M, Chen X, Liu H, Wang Q, Guo M, et al. CAR-armored-cell therapy in solid tumor treatment. Journal of Translational Medicine. 2024. https:\/\/doi.org\/10.1186\/s12967-024-05903-3.","journal-title":"Journal of Translational Medicine"},{"key":"4389_CR222","doi-asserted-by":"crossref","unstructured":"Erik Wennerberg 1 VK. Richard Childs 2, Andreas Lundqvist CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother. 2014.","DOI":"10.1007\/s00262-014-1629-5"},{"key":"4389_CR223","doi-asserted-by":"crossref","unstructured":"Zhu H, Kaufman DS. An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells. Vitro Differentiation of T-Cells: Methods and Protocols. Springer; 2019. pp. 107\u201319.","DOI":"10.1007\/978-1-4939-9728-2_12"},{"issue":"6","key":"4389_CR224","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-19. e10.","journal-title":"Cell"},{"issue":"2","key":"4389_CR225","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;22(2):251\u20136.","journal-title":"Mol Ther"},{"key":"4389_CR226","unstructured":"Suck G, Odendahl M, Nowakowska P et al. NK cells expanded in vitro from cancer patients express activating receptors and show cytotoxic activity against tumor cell lines and autologous primary tumor cells. J Cell Mol Med. 2010."},{"issue":"8","key":"4389_CR227","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.20051511","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F, M\u00e9nard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4\u2009+\u2009CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor\u2013\u03b2\u2013dependent manner. J Exp Med. 2005;202(8):1075\u201385.","journal-title":"J Exp Med"},{"issue":"6","key":"4389_CR228","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/eji.201344272","volume":"44","author":"M Vitale","year":"2014","unstructured":"Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 2014;44(6):1582\u201392.","journal-title":"Eur J Immunol"},{"key":"4389_CR229","doi-asserted-by":"crossref","unstructured":"Mahmoud Mohammad Yaseen 1. Nizar Mohammad Abuharfeil 1, Homa Darmani 2, Ammar Daoud 3. Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine. Open Biol. 2020.","DOI":"10.1098\/RSOB.200111\/v2\/response1"},{"issue":"7","key":"4389_CR230","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor \u03b21 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences. 2003;100(7):4120\u20135.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"4389_CR231","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.4049\/jimmunol.181.6.3784","volume":"181","author":"R Trotta","year":"2008","unstructured":"Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, et al. TGF-\u03b2 utilizes SMAD3 to inhibit CD16-mediated IFN-\u03b3 production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181(6):3784\u201392.","journal-title":"J Immunol"},{"issue":"1","key":"4389_CR232","doi-asserted-by":"publisher","first-page":"e0191358","DOI":"10.1371\/journal.pone.0191358","volume":"13","author":"F Otegbeye","year":"2018","unstructured":"Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, et al. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS ONE. 2018;13(1):e0191358.","journal-title":"PLoS ONE"},{"key":"4389_CR233","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/ITT.S512700","volume":"14","author":"V \u0160vubov\u00e1","year":"2025","unstructured":"\u0160vubov\u00e1 V, Janstov\u00e1 L, Jedli\u010dka M, Ma\u0161\u00ednov\u00e1 E, Szabov\u00e1 J, Feglarov\u00e1 T, et al. TGF-\u03b2 Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment. Immunotargets Ther. 2025;14:589\u2013604.","journal-title":"Immunotargets Ther"},{"issue":"2","key":"4389_CR234","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.intimp.2013.06.003","volume":"17","author":"B Yang","year":"2013","unstructured":"Yang B, Liu H, Shi W, Wang Z, Sun S, Zhang G, et al. Blocking transforming growth factor-\u03b2 signaling pathway augments antitumor effect of adoptive NK-92 cell therapy. Int Immunopharmacol. 2013;17(2):198\u2013204.","journal-title":"Int Immunopharmacol"},{"key":"4389_CR235","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86621","author":"S Herbertz","year":"2015","unstructured":"Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug design, development and therapy. 2015. https:\/\/doi.org\/10.2147\/DDDT.S86621.","journal-title":"Drug design, development and therapy"},{"issue":"3","key":"4389_CR236","doi-asserted-by":"publisher","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9(3):e90353.","journal-title":"PLoS ONE"},{"issue":"4","key":"4389_CR237","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","volume":"26","author":"A Rea","year":"2025","unstructured":"Rea A, Santana-Hern\u00e1ndez S, Villanueva J, Sanvicente-Garc\u00eda M, Cabo M, Suarez-Olmos J, et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression. Nat Immunol. 2025;26(4):582\u201394.","journal-title":"Nat Immunol"},{"key":"4389_CR238","unstructured":"Jackie E, Bader 1 KV, Jeffrey C, Rathmell. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2021."},{"key":"4389_CR239","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3389\/fimmu.2018.02533","volume":"9","author":"AM Chambers","year":"2018","unstructured":"Chambers AM, Wang J, Lupo KB, Yu H, Atallah Lanman NM, Matosevic S. Adenosinergic Signaling Alters Natural Killer Cell Functional Responses. Front Immunol. 2018;9:2533.","journal-title":"Front Immunol"},{"issue":"10","key":"4389_CR240","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1002\/eji.201343448","volume":"43","author":"M Balsamo","year":"2013","unstructured":"Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, et al. Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol. 2013;43(10):2756\u201364.","journal-title":"Eur J Immunol"},{"key":"4389_CR241","unstructured":"Leslie D, Leve 1 JMN, Daniel S, Shaw J, Ganiban MN, Natsuaki D, Reiss. The Early Growth and Development Study: a prospective adoption study from birth through middle childhood. Twin Res Hum Genet Mol Cancer. 2013."},{"issue":"1","key":"4389_CR242","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","volume":"6","author":"J Wang","year":"2018","unstructured":"Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer. 2018;6(1):136.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4389_CR243","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"issue":"7","key":"4389_CR244","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723\u201332.","journal-title":"Nat Immunol"},{"issue":"13","key":"4389_CR245","first-page":"2286","volume":"116","author":"DM Benson Jr","year":"2010","unstructured":"Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody. Blood J Am Soc Hematol. 2010;116(13):2286\u201394.","journal-title":"Blood J Am Soc Hematol"},{"issue":"26","key":"4389_CR246","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"key":"4389_CR247","doi-asserted-by":"crossref","unstructured":"Murali Shankar N, Ortiz-Montero P, Kurzyukova A, Rackwitz W, Kuenzel S, Wels W et al. Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1254821"},{"key":"4389_CR248","doi-asserted-by":"crossref","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L. CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol. 2025;Volume 16\u20132025.","DOI":"10.3389\/fimmu.2025.1574742"},{"issue":"1","key":"4389_CR249","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"L Ran Gh","year":"2022","unstructured":"Ran Gh L, Yq, Tian L, Zhang T, Yan Dm Y, Jh, et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Therapy. 2022;7(1):205.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"4389_CR250","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13046-023-02918-4","volume":"43","author":"S Santana-Hern\u00e1ndez","year":"2024","unstructured":"Santana-Hern\u00e1ndez S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, et al. NK cell-triggered CCL5\/IFN\u03b3-CXCL9\/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Cancer Res. 2024;43(1):10.","journal-title":"J Exp Clin Cancer Res"},{"key":"4389_CR251","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","volume":"59","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S. Chemokine networks modulating natural killer cell trafficking to solid tumors. Cytokine Growth Factor Rev. 2021;59:36\u201345.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"4389_CR252","doi-asserted-by":"publisher","first-page":"1802045","DOI":"10.1002\/advs.201802045","volume":"6","author":"R El Assal","year":"2019","unstructured":"El Assal R, Abou-Elkacem L, Tocchio A, Pasley S, Matosevic S, Kaplan DL, et al. Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy. Adv Sci (Weinh). 2019;6(6):1802045.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"4389_CR253","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40259-021-00494-7","volume":"35","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S. Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy. BioDrugs. 2021;35(5):529\u201345.","journal-title":"BioDrugs"},{"key":"4389_CR254","doi-asserted-by":"publisher","first-page":"1304689","DOI":"10.3389\/fimmu.2023.1304689","volume":"14","author":"JN Saultz","year":"2023","unstructured":"Saultz JN, Otegbeye F. Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. Front Immunol. 2023;14:1304689.","journal-title":"Front Immunol"},{"issue":"2","key":"4389_CR255","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1021\/acs.molpharmaceut.3c00798","volume":"21","author":"S Das","year":"2024","unstructured":"Das S, Niemeyer E, Leung ZA, Fritsch T, Matosevic S. Human Natural Killer Cells Cryopreserved without DMSO Sustain Robust Effector Responses. Mol Pharm. 2024;21(2):651\u201360.","journal-title":"Mol Pharm"},{"issue":"5","key":"4389_CR256","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jcyt.2025.01.012","volume":"27","author":"A Joules","year":"2025","unstructured":"Joules A, Mallya AS, Louwagie T, Yu G, Hubel A. Probing mechanisms of cryopreservation damage to natural killer cells. Cytotherapy. 2025;27(5):649\u201360.","journal-title":"Cytotherapy"},{"key":"4389_CR257","doi-asserted-by":"crossref","unstructured":"Saultz JN, Otegbeye F. Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. Front Immunol. 2023;Volume 14\u20132023.","DOI":"10.3389\/fimmu.2023.1304689"},{"issue":"1","key":"4389_CR258","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","volume":"15","author":"A Berjis","year":"2024","unstructured":"Berjis A, Muthumani D, Aguilar OA, Pomp O, Johnson O, Finck AV, et al. Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat Commun. 2024;15(1):3937.","journal-title":"Nat Commun"},{"issue":"2","key":"4389_CR259","doi-asserted-by":"publisher","first-page":"201749","DOI":"10.1016\/j.omta.2026.201749","volume":"34","author":"E J\u00e4rvel\u00e4","year":"2026","unstructured":"J\u00e4rvel\u00e4 E, Koski J, Jahan F, Tuhkala A, Saari M, Elmadani M, et al. Efficient NK cell transduction with VSV-G-pseudotyped lentiviral vectors. Mol Therapy Adv. 2026;34(2):201749.","journal-title":"Mol Therapy Adv"},{"issue":"5","key":"4389_CR260","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jleuko\/qiad074","volume":"114","author":"T Bexte","year":"2023","unstructured":"Bexte T, Reindl LM, Ullrich E. Nonviral technologies can pave the way for CAR-NK cell therapy. J Leukoc Biol. 2023;114(5):475\u201386.","journal-title":"J Leukoc Biol"},{"issue":"48","key":"4389_CR261","doi-asserted-by":"publisher","first-page":"2410908","DOI":"10.1002\/adma.202410908","volume":"36","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Harberts J, Assadi A, Chen Y, Spatz JP, Duan W, et al. The Roles of Micro-and Nanoscale Materials in Cell\u2010Engineering Systems. Adv Mater. 2024;36(48):2410908.","journal-title":"Adv Mater"},{"key":"4389_CR262","doi-asserted-by":"crossref","unstructured":"Saari M, Jahan F, Andersson L, Syreeni A, Vehmaan-Kreula P, Koski J et al. Feeder cell-the key component in producing scalable and fit NK cells for therapeutic use. bioRxiv. 2026:2026.04. 21.718880.","DOI":"10.64898\/2026.04.21.718880"},{"key":"4389_CR263","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.802906","volume":"13","author":"M Gurney","year":"2022","unstructured":"Gurney M, Kundu S, Pandey S, O\u2019Dwyer M. Feeder cells at the interface of natural killer cell activation, expansion and gene editing. Frontiers in Immunology. 2022;13:802906.","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"4389_CR264","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1002\/mco2.740","volume":"5","author":"F Gao","year":"2024","unstructured":"Gao F, Mora MC, Constantinides M, Co\u00ebnon L, Multrier C, Vaillant L, et al. Feeder cell training shapes the phenotype and function of in vitro expanded natural killer cells. MedComm. 2024;5(10):e740.","journal-title":"MedComm"},{"issue":"9","key":"4389_CR265","doi-asserted-by":"publisher","first-page":"e1219007","DOI":"10.1080\/2162402X.2016.1219007","volume":"5","author":"M Granzin","year":"2016","unstructured":"Granzin M, Stojanovic A, Miller M, Childs R, Huppert V, Cerwenka A. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology. 2016;5(9):e1219007.","journal-title":"Oncoimmunology"},{"issue":"12","key":"4389_CR266","doi-asserted-by":"publisher","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","volume":"9","author":"I Christodoulou","year":"2021","unstructured":"Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9(12):e003894.","journal-title":"J Immunother Cancer"},{"key":"4389_CR267","doi-asserted-by":"crossref","unstructured":"Vijayashankar DP, Thaikkattil B, Sharma D, Chougule S, Ramachandra M, Kumar A, et al. 288 Novel IL-15 modules promote long-term persistence, repeated tumor killing and self-sustenance of chimeric antigen receptor-natural killer (CAR-NK) cells manufactured using an indigenous platform. BMJ Publishing Group Ltd; 2025.","DOI":"10.1136\/jitc-2025-SITC2025.0288"},{"issue":"1","key":"4389_CR268","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13046-023-02770-6","volume":"42","author":"T Nakazawa","year":"2023","unstructured":"Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al. CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma. J Exp Clin Cancer Res. 2023;42(1):205.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"4389_CR269","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.70152","volume":"50","author":"X Lyu","year":"2026","unstructured":"Lyu X, Zhu N, Guo R, Yuldasheyv J. CAR-NK cell biology and engineering for solid tumors, with a focus on lung cancer. Cell Biology International. 2026;50(4):e70152.","journal-title":"Cell Biology International"},{"key":"4389_CR270","unstructured":"Wang Q. Genetic Engineering a TGF-beta1 Tolerant Human Natural Killer Cell Line for Effective Anticancer Immunotherapy. The Chinese University of Hong Kong (Hong Kong); 2016."},{"key":"4389_CR271","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626098","volume":"12","author":"E Liu","year":"2021","unstructured":"Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, et al. GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells. Front Immunol. 2021;12:626098.","journal-title":"Front Immunol"},{"key":"4389_CR272","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27196","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian K, Zhang D, Hu P, He Z, et al. CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27196.","journal-title":"Heliyon"},{"issue":"6","key":"4389_CR273","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.ymthe.2024.12.057","volume":"33","author":"H Hosseinalizadeh","year":"2025","unstructured":"Hosseinalizadeh H, Wang L-S, Mirzaei H, Amoozgar Z, Tian L, Yu J. Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Molecular Therapy. 2025;33(6):2406\u201325.","journal-title":"Molecular Therapy"},{"issue":"5","key":"4389_CR274","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41587-024-02319-8","volume":"43","author":"CRISPR screens of","year":"2025","unstructured":"CRISPR screens of. tumor-infiltrating NK cells identify genetic checkpoints for CAR-NK therapy. Nat Biotechnol. 2025;43(5):696\u20137.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4389_CR275","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-014-1629-5","volume":"64","author":"E Wennerberg","year":"2015","unstructured":"Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother. 2015;64(2):225\u201335.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4389_CR276","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1186\/s12967-024-05724-4","volume":"22","author":"X Lin","year":"2024","unstructured":"Lin X, Liu Z, Dong X, Wang K, Sun Y, Zhang H, et al. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. J Translational Med. 2024;22(1):929.","journal-title":"J Translational Med"},{"issue":"6","key":"4389_CR277","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4389_CR278","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5483\/BMBRep.2023-0024","volume":"56","author":"M Choi","year":"2023","unstructured":"Choi M, Shin J, Lee CE, Chung JY, Kim M, Yan X, et al. Immunogenic cell death in cancer immunotherapy. BMB Rep. 2023;56(5):275\u201386.","journal-title":"BMB Rep"},{"key":"4389_CR279","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001334","author":"J Eitler","year":"2021","unstructured":"Eitler J, Wotschel N, Miller N, Boissel L, Klingemann HG, Wels W, et al. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001334.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4389_CR280","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","volume":"17","author":"A Van den Eynde","year":"2024","unstructured":"Van den Eynde A, Gehrcken L, Verhezen T, Lau HW, Hermans C, Lambrechts H, et al. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol. 2024;17(1):8.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4389_CR281","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","volume":"10","author":"J Luo","year":"2025","unstructured":"Luo J, Guo M, Huang M, Liu Y, Qian Y, Liu Q, et al. Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation. Signal Transduct Target Ther. 2025;10(1):78.","journal-title":"Signal Transduct Target Ther"},{"key":"4389_CR282","doi-asserted-by":"publisher","first-page":"586168","DOI":"10.3389\/fimmu.2020.586168","volume":"11","author":"K Hoerster","year":"2020","unstructured":"Hoerster K, Uhrberg M, Wiek C, Horn PA, Hanenberg H, Heinrichs S. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for Off-the-Shelf Immunotherapy. Front Immunol. 2020;11:586168.","journal-title":"Front Immunol"},{"issue":"5","key":"4389_CR283","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41587-024-02282-4","volume":"43","author":"L Peng","year":"2025","unstructured":"Peng L, Renauer PA, Sferruzza G, Yang L, Zou Y, Fang Z, et al. In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat Biotechnol. 2025;43(5):752\u201361.","journal-title":"Nat Biotechnol"},{"key":"4389_CR284","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01008","volume":"11","author":"RS Huang","year":"2020","unstructured":"Huang RS, Shih HA, Lai MC, Chang YJ, Lin S. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins. Front Immunol. 2020;11:1008.","journal-title":"Front Immunol"},{"issue":"1","key":"4389_CR285","doi-asserted-by":"publisher","first-page":"e20230030","DOI":"10.1002\/INMD.20230030","volume":"2","author":"C Wang","year":"2024","unstructured":"Wang C, Wang C, Liu H, Zhao S, Qiu J, Li P, et al. Immune function assessing of TIM3\/CD28-modified CD19 CAR\u2010T cells and general CD19 CAR\u2010T cells through a high\u2010throughput single\u2010cell microarray platform. Interdisciplinary Med. 2024;2(1):e20230030.","journal-title":"Interdisciplinary Med"},{"issue":"1","key":"4389_CR286","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12943-024-02151-3","volume":"23","author":"X Zhu","year":"2024","unstructured":"Zhu X, Xue J, Jiang H, Xue D. CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside. Mol Cancer. 2024;23(1):237.","journal-title":"Mol Cancer"},{"key":"4389_CR287","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/ITT.S490498","volume":"13","author":"S Chen","year":"2024","unstructured":"Chen S, Yang L, Xia B, Zhu H, Piao Z, Jounaidi Y. A Self-Activating IL-15 Chimeric Cytokine Receptor to Empower Cancer Immunotherapy. Immunotargets Ther. 2024;13:513\u201324.","journal-title":"Immunotargets Ther"},{"issue":"48","key":"4389_CR288","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113(48):E7788\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"4389_CR289","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","volume":"31","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhu Y, Yang L. IL-15 in CAR engineering: striking an efficacy\u2013safety balance. Trends Mol Med. 2025;31(11):977\u201381.","journal-title":"Trends Mol Med"},{"issue":"5","key":"4389_CR290","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41587-024-02282-4","volume":"43","author":"L Peng","year":"2025","unstructured":"Peng L, Renauer PA, Sferruzza G, Yang L, Zou Y, Fang Z, et al. In vivo AAV\u2013SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat Biotechnol. 2025;43(5):752\u201361.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"4389_CR291","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.ccell.2025.07.021","volume":"43","author":"A Biederst\u00e4dt","year":"2025","unstructured":"Biederst\u00e4dt A, Basar R, Park J-M, Uprety N, Shrestha R, Silva FR, et al. Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell. 2025;43(11):2069-88. e11.","journal-title":"Cancer cell"},{"issue":"7","key":"4389_CR292","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731-43. e13.","journal-title":"Cell"},{"issue":"1","key":"4389_CR293","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1134\/S0026893320010100","volume":"54","author":"G Kochneva","year":"2020","unstructured":"Kochneva G, Sivolobova G, Tkacheva A, Gorchakov A, Kulemzin S. Combination of oncolytic virotherapy and CAR T\/NK cell therapy for the treatment of cancer. Molecular Biology. 2020;54(1):1\u201312.","journal-title":"Molecular Biology"},{"issue":"1","key":"4389_CR294","doi-asserted-by":"publisher","first-page":"e000131","DOI":"10.1136\/jitc-2019-000131","volume":"8","author":"F Li","year":"2020","unstructured":"Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S, et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 2020;8(1):e000131.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4389_CR295","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","volume":"25","author":"HJ Chon","year":"2019","unstructured":"Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clinical Cancer Research. 2019;25(5):1612\u201323.","journal-title":"Clinical Cancer Research"},{"key":"4389_CR296","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.561372","volume":"10","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang X, Cheng P. Remodeling of tumor immune microenvironment by oncolytic viruses. Frontiers in Oncology. 2021;10:561372.","journal-title":"Frontiers in Oncology"},{"key":"4389_CR297","first-page":"582","volume":"23","author":"Z Du","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S. PiggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. Molecular Therapy. 2021;23:582\u201396.","journal-title":"Molecular Therapy"},{"key":"4389_CR298","unstructured":"Hamed Hosseinalizadeh 1 L-SW. Hamed Mirzaei 3, Zohreh Amoozgar 4, Lei Tian 5, Jianhua Yu. Emerging combined CAR-NK cell therapies in cancer treatment: Finding a dancing partner. Mol Ther Mol Cancer. 2025."},{"issue":"4","key":"4389_CR299","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040811","volume":"9","author":"P Oberoi","year":"2020","unstructured":"Oberoi P, Kamenjarin K, Villena Ossa JF, Uherek B, B\u00f6nig H, Wels WS. Directed differentiation of mobilized hematopoietic stem and progenitor cells into functional NK cells with enhanced antitumor activity. Cells. 2020;9(4):811.","journal-title":"Cells"},{"issue":"17","key":"4389_CR300","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"issue":"9","key":"4389_CR301","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.4049\/jimmunol.2100970","volume":"209","author":"K Klausz","year":"2022","unstructured":"Klausz K, Pekar L, Boje AS, Gehlert CL, Krohn S, Gupta T, et al. Multifunctional NK Cell\u2013Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release. J Immunol. 2022;209(9):1724\u201335.","journal-title":"J Immunol"},{"key":"4389_CR302","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039969","author":"SK Nikkhoi","year":"2023","unstructured":"Nikkhoi SK, Li G, Eleya S, Yang G, Vandavasi VG, Hatefi A. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Frontiers in Immunology. 2023. https:\/\/doi.org\/10.3389\/fimmu.2022.1039969.","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"4389_CR303","doi-asserted-by":"publisher","first-page":"e4593","DOI":"10.1002\/pro.4593","volume":"32","author":"B Lipinski","year":"2023","unstructured":"Lipinski B, Arras P, Pekar L, Klewinghaus D, Boje AS, Krah S, et al. NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Sci. 2023;32(3):e4593.","journal-title":"Protein Sci"},{"issue":"19","key":"4389_CR304","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.1016\/S0021-9258(18)48095-7","volume":"262","author":"RM Johnstone","year":"1987","unstructured":"Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262(19):9412\u201320.","journal-title":"J Biol Chem"},{"key":"4389_CR305","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715000","author":"K Kim","year":"2021","unstructured":"Kim K, Gwak H-S, Han N, Hong EK, Choi BK, Lee S, et al. Chimeric antigen receptor T cells with modified interleukin-13 preferentially recognize IL13R\u03b12 and suppress malignant glioma: a preclinical study. Frontiers in Immunology. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.715000.","journal-title":"Frontiers in Immunology"},{"issue":"23","key":"4389_CR306","doi-asserted-by":"publisher","first-page":"37783","DOI":"10.18632\/oncotarget.16354","volume":"8","author":"Y Xia","year":"2017","unstructured":"Xia Y, Zhang Q, Zhen Q, Zhao Y, Liu N, Li T, et al. Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway. Oncotarget. 2017;8(23):37783\u201395.","journal-title":"Oncotarget"},{"issue":"6","key":"4389_CR307","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/cancers11060874","volume":"11","author":"J Zhao","year":"2019","unstructured":"Zhao J, Schl\u00f6\u00dfer HA, Wang Z, Qin J, Li J, Popp F, et al. Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Cancers. 2019;11(6):874.","journal-title":"Cancers"},{"key":"4389_CR308","doi-asserted-by":"publisher","first-page":"e73699","DOI":"10.7554\/eLife.73699","volume":"11","author":"AM Chambers","year":"2022","unstructured":"Chambers AM, Lupo KB, Wang J, Cao J, Utturkar S, Lanman N, et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. Elife. 2022;11:e73699.","journal-title":"Elife"},{"issue":"1","key":"4389_CR309","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41523-024-00618-6","volume":"10","author":"J Mei","year":"2024","unstructured":"Mei J, Cai Y, Zhu H, Jiang Y, Fu Z, Xu J, et al. High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. npj Breast Cancer. 2024;10(1):11.","journal-title":"npj Breast Cancer"},{"issue":"1","key":"4389_CR310","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12885-022-09294-w","volume":"22","author":"S Si","year":"2022","unstructured":"Si S, Wang L, Cao H, Xu Y, Zhan Q. Co-deficiency of B7-H3 and B7-H4 identifies high CD8\u2009+\u2009T cell infiltration and better prognosis in pancreatic cancer. BMC Cancer. 2022;22(1):211.","journal-title":"BMC Cancer"},{"key":"4389_CR311","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1016\/j.csbj.2022.09.021","volume":"20","author":"K-H Bai","year":"2022","unstructured":"Bai K-H, Zhang Y-Y, Li X-P, Tian X-P, Pan M-M, Wang D-W, et al. Comprehensive analysis of tumor necrosis factor-\u03b1-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint. Comput Struct Biotechnol J. 2022;20:5226\u201334.","journal-title":"Comput Struct Biotechnol J"},{"key":"4389_CR312","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","volume":"59","author":"F Finkelmeier","year":"2016","unstructured":"Finkelmeier F, Canli \u00d6, Tal A, Pleli T, Trojan J, Schmidt M, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer. 2016;59:152\u20139.","journal-title":"Eur J Cancer"},{"key":"4389_CR313","doi-asserted-by":"publisher","first-page":"107467","DOI":"10.1016\/j.intimp.2021.107467","volume":"94","author":"T Mocan","year":"2021","unstructured":"Mocan T, Ilies M, Nenu I, Craciun R, Horhat A, Susa R, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol. 2021;94:107467.","journal-title":"Int Immunopharmacol"},{"key":"4389_CR314","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2020.07.016","volume":"326","author":"YE Lee","year":"2020","unstructured":"Lee YE, Ju A, Choi HW, Kim J-C, Kim EE, Kim TS, et al. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. J Control Release. 2020;326:310\u201323.","journal-title":"J Control Release"},{"issue":"10","key":"4389_CR315","doi-asserted-by":"publisher","first-page":"e003050","DOI":"10.1136\/jitc-2021-003050","volume":"9","author":"C-I Jan","year":"2021","unstructured":"Jan C-I, Huang S-W, Canoll P, Bruce JN, Lin Y-C, Pan C-M, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021;9(10):e003050.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"4389_CR316","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.18632\/oncotarget.8526","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7(19):27764\u201377.","journal-title":"Oncotarget"},{"issue":"1","key":"4389_CR317","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/or.2020.7862","volume":"33","author":"H Liu","year":"2015","unstructured":"Liu H, Yang B, Sun T, Lin L, Hu Y, Deng M, et al. Specific growth inhibition of ErbB2\u2013expressing human breast cancer cells by genetically modified NK\u201392 cells. Oncol Rep. 2015;33(1):95\u2013102.","journal-title":"Oncol Rep"},{"issue":"16","key":"4389_CR318","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-08-0536","volume":"14","author":"PL Crispen","year":"2008","unstructured":"Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2008;14(16):5150\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4389_CR319","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41523-024-00618-6","volume":"10","author":"J Mei","year":"2024","unstructured":"Mei J, Cai Y, Zhu H, Jiang Y, Fu Z, Xu J, et al. High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. NPJ Breast Cancer. 2024;10(1):11.","journal-title":"NPJ Breast Cancer"},{"key":"4389_CR320","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659662","volume":"11","author":"C Long","year":"2021","unstructured":"Long C, Li G, Zhang C, Jiang T, Li Y, Duan X, et al. B7-H3 as a target for CAR-T cell therapy in skull base chordoma. Front Oncol. 2021;11:659662.","journal-title":"Front Oncol"},{"issue":"19","key":"4389_CR321","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197050","volume":"21","author":"IJ Purvis","year":"2020","unstructured":"Purvis IJ, Velpula KK, Guda MR, Nguyen D, Tsung AJ, Asuthkar S. B7-H3 in medulloblastoma-derived exosomes; a novel tumorigenic role. Int J Mol Sci. 2020;21(19):7050.","journal-title":"Int J Mol Sci"},{"key":"4389_CR322","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1130442","author":"B He","year":"2023","unstructured":"He B, Mai Q, Pang Y, Deng S, He Y, Xue R, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Frontiers in Immunology. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1130442.","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"4389_CR323","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","volume":"28","author":"KV Woan","year":"2021","unstructured":"Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell. 2021;28(12):2062-75.e5.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"4389_CR324","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","volume":"4","author":"X Wang","year":"2020","unstructured":"Wang X, Jasinski DL, Medina JL, Spencer DM, Foster AE, Bayle JH. Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 2020;4(9):1950\u201364.","journal-title":"Blood Adv"},{"issue":"8","key":"4389_CR325","doi-asserted-by":"publisher","first-page":"e002866","DOI":"10.1136\/jitc-2021-002866","volume":"9","author":"M Bachiller","year":"2021","unstructured":"Bachiller M, Perez-Amill L, Battram AM, Carn\u00e9 SC, Najjar A, Verhoeyen E, et al. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer. 2021;9(8):e002866.","journal-title":"J Immunother Cancer"}],"updated-by":[{"DOI":"10.1186\/s12935-026-04470-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000}}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04389-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:06:55Z","timestamp":1790060815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04389-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":325,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4389"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04389-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The Author group information has been updated in the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12935-026-04470-5","URL":"https:\/\/doi.org\/10.1186\/s12935-026-04470-5","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"299"}}